Posts filtered by tags: Alzheimer's Drugs[x]


 

Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatment

Westend61/ Shares of Cassava Sciences jumped as much as 16% on Monday on news that it successfully completed an end-of-phase two meeting with the FDA for its Alzheimer's treatment Simufilam. The biotech company will be moving forward with a pivotal phase-three study in the second half of this year.  Simufilam is a novel drug that targets "both neuroinflammation and neurodegeneration. Sign up here for our daily newsletter, 10 Things Before the Opening Bell Shares of Cassava Sciences jumped...
Tags: Trends, Markets, Alzheimer's Disease, Trading, Fda, Stock Market, Austin Texas, Alzheimer's Drugs, Isabelle Lee, Cassava Sciences, Remi Barbier, Simufilam, Opening Bell Shares of Cassava Sciences, US Food and Drug Administration for Simufilam, Rubicon Simufilam, Alzheimer s Association Shares of Cassava Sciences


Cassava Sciences soars over 200% to 10-year high on positive Alzheimer's treatment data

Westend61/ Shares of Cassava Sciences soared over 200% Tuesday after the company announced positive data on its leading drug candidate for the treatment of Alzheimer's disease. The stock price of Cassava Sciences surged toward an almost 10-year high, on track to close at its highest level since June 2011.  Simufilam, the drug candidate, improved the cognition and behavior of patients following six months of treatment. Sign up here for our daily newsletter, 10 Things Before the Opening Bel...
Tags: Trends, Markets, Trading, Stock Market, Austin Texas, Alzheimer s Association, Alzheimer's Drugs, Stock Market News, Biopharma Stocks, Isabelle Lee, Cassava Sciences, Remi Barbier


Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee

Getty Images / Xinhua News Agency Biogen plummeted 32% on Monday after the FDA Advisory Committee signaled that it is unconvinced Biogen's Alzheimer's therapy is effective in combating the disease.On Friday, the FDA AdCom voted 8-1 that data from the phase 3 EMERGE study evaluating Biogen's aducanumab in patients with mild Alzheimer's disease was not enough to show efficacy.The negative AdCom vote came two days after FDA scientists said in a document release that aducanumab data was "excep...
Tags: Japan, Finance, Trends, Markets, Trading, Stocks, Alzheimer's, Fda, Biotech, Stock Market, Morgan Stanley, Biotechnology, McDonald, Biogen, FDA Advisory Committee, Matthew Fox


How Biogen’s Experimental Alzheimer’s Drug Was Resurrected From the Dead

In a surprising twist, Biogen announced it will file for FDA approval of its Alzheimer’s drug, after stopping its study of the therapy last spring
Tags: News, Uncategorized, Brain, Alzheimer's, Fda, Biogen, Alzheimer's Drugs, HealthSummit19


How Biogen’s Discontinued Alzheimer’s Drug Got A Second Life

In a surprising twist, Biogen announced it will file for FDA approval of its Alzheimer’s drug, after stopping its study of the therapy last spring
Tags: News, Uncategorized, Brain, Alzheimer's, Fda, Biogen, Alzheimer's Drugs, HealthSummit19